- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06559709
A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
September 4, 2025 updated by: Fred Hutchinson Cancer Center
Implementing a Plant-Based Whole-Foods Meal Delivery Service for Patients Undergoing Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: A Pilot Study
This clinical trial evaluates the impact of a plant-based whole-foods delivery service on the microbiome in patients with multiple myeloma undergoing an autologous hematopoietic cell transplant.
An autologous hematopoietic cell transplant is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person.
Loss of microbial diversity within the intestinal tract has been associated with poor outcomes for patients receiving autologous stem cell transplantation.
A plant-based whole meal delivery service may increase the intake of foods high in fiber and nutrients therefore improve microbial health during the peri-transplant period.
In this pilot study, study investigators will explore the feasibility of this approach.
Study Overview
Status
Completed
Conditions
Detailed Description
OUTLINE:
Patients receive 3 meals per day and snacks delivered twice weekly and meet with dietitian once weekly on days -7 to 28. Patients undergo blood and stool sample collection on study.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Able to provide written informed consent prior to initiation of any study procedures
- Planned first autologous stem cell transplantation for multiple myeloma
- Planned outpatient treatment for the duration of transplantation (if admitted, the investigators will request that caregivers bring the meals/snacks to the hospital as they might with other food prepared at home)
- Access to a refrigerator
- Ability to reheat foods
- Able to consume an oral diet at enrollment
- Able to communicate clearly regarding aspects of the study: e.g. Give feedback on logistics and meals, in order to maximize the operational data the investigators can gather in this pilot study
- At least 18 years of age
Exclusion Criteria:
- Major psychiatric diagnosis that impairs cognitive functioning or is not controlled at the time of the approach, as judged by the patient's medical team
- Planned inpatient transplantation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Supportive care (meal delivery service)
Patients receive 3 meals per day and snacks delivered twice weekly and meet with dietitian once weekly on days -7 to 28.
Patients undergo blood and stool sample collection on study.
|
Ancillary studies
Ancillary studies
Other Names:
Undergo blood and stool sample collection
Other Names:
Receive 3 meals per day and snacks
Other Names:
Meet with dietitian
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Enrollment rate
Time Frame: Up to 1 year
|
The proportion of eligible patients who consent to enroll in the study will be computed based on the number approached and estimated with 95% confidence intervals.
Reasons for non-participation will be summarized.
|
Up to 1 year
|
|
Collection rate
Time Frame: Up to 1 month post transplant
|
Collection rate will be the percentage of stool samples, blood samples and surveys collected.
|
Up to 1 month post transplant
|
|
Tolerability of the delivered diet: Patient opinion
Time Frame: Up to 1 month post transplant
|
Patient opinion of the delivered meals will be assessed using qualitative end-study surveys.
|
Up to 1 month post transplant
|
|
Tolerability of the delivered diet: Proportion of meals consumed
Time Frame: Up to 1 month post transplant
|
Patient acceptability of the delivered meals will be assessed using proportions of the delivered meals consumed based on multi-day food diaries and 24-hour recall assessments.
|
Up to 1 month post transplant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kate Markey, Fred Hutch/University of Washington Cancer Consortium
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 14, 2024
Primary Completion (Actual)
August 29, 2025
Study Completion (Actual)
August 29, 2025
Study Registration Dates
First Submitted
July 15, 2024
First Submitted That Met QC Criteria
August 16, 2024
First Posted (Actual)
August 19, 2024
Study Record Updates
Last Update Posted (Estimated)
September 8, 2025
Last Update Submitted That Met QC Criteria
September 4, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Neoplasms, Plasma Cell
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Hemic and Lymphatic Diseases
- Multiple Myeloma
- Investigative Techniques
- Therapeutics
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Nutrition Therapy
- Specimen Handling
- Diet Therapy
Other Study ID Numbers
- RG1124594
- NCI-2024-05448 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 20501 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.